Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Product Portfolio, Meda
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Receptos to deliver scientific presentation at Digestive Disease Week 2012 about the therapeutic role of RPC1063 in inflammatory bowel disease
Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients.
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Pathogenic implications of iron accumulation in multiple sclerosis.
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
Extavia Prescribing Information
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Multiple sclerosis: clinical presentation, diagnosis and treatment.
Posturography in MS patients treated with high dose methylprednisolone.
Regenerative cellular therapies for neurologic diseases.
Guillain-Barré Syndrome (42 Cases) Occurring During a Zika Virus Outbreak in French Polynesia.
Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Bioengineered cell culture systems of central nervous system injury and disease.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial.
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Pages